Peacekat, I completely agree. It is a challenge
Post# of 145810
I completely agree. It is a challenge with a new disease and shifting expectations to guess correctly when designing trials. Though only P2, CD10 was successful.
Unfortunately m/m not a clinical indication about which fda seems to care any longer.
Severe/critical and long haulers/persistent dysfunction seem to be current focus.
Hopefully Cytodyn is ahead of us and following up with CD10 and EIND patients as suggested by Rubraquercus.
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)